Payment overview · 2025
General Payments
$191.38
11 reported records · 8 companies
Healthcare provider profile · identity verified
Veerappan Sundar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HENDERSON, NC · NPI 1144298886
Verified facts
What the public records show
CMS Open Payments records show Veerappan Sundar, MD received $191.38 in general payments during 2025 across 11 reported records.
GlaxoSmithKline, LLC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.58 | 25.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.17 | 19.4% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.43 | 11.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.27 | 10.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.81 | 9.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.44 | 9.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.14 | 7.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.54 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.38 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1018 | 221 |
| Atorvastatin Calcium | Atorvastatin Calcium | 764 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 620 | 128 |
| Losartan Potassium | Losartan Potassium | 580 | 130 |
| Lisinopril | Lisinopril | 458 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 423 | 93 |
| Gabapentin | Gabapentin | 389 | 86 |
| Metformin Hcl | Metformin Hcl | 341 | 79 |
| Furosemide | Furosemide | 280 | 63 |
| Spironolactone | Spironolactone | 269 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 264 | 43 |
| Allopurinol | Allopurinol | 247 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 233 | 52 |
| Omeprazole | Omeprazole | 230 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 225 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 35 |
| Prednisone | Prednisone | 187 | 104 |
| Glipizide Er | Glipizide | 183 | 36 |
| Jardiance | Empagliflozin | 177 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 40 |
| Famotidine | Famotidine | 173 | 42 |
| Sertraline Hcl | Sertraline Hcl | 172 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 38 |
| Eliquis | Apixaban | 134 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 129 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 31 |
| Carvedilol | Carvedilol | 104 | 23 |
| Metformin Hcl Er | Metformin Hcl | 100 | 25 |
| Trazodone Hcl | Trazodone Hcl | 97 | 20 |
| Glipizide | Glipizide | 94 | 18 |
| Trulicity | Dulaglutide | 93 | 15 |
| Potassium Chloride | Potassium Chloride | 92 | 21 |
| Atenolol | Atenolol | 86 | 20 |
| Glimepiride | Glimepiride | 83 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 22 |
| Meloxicam | Meloxicam | 74 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 26 |
| Cephalexin | Cephalexin | 69 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 61 | 11 |
| Ezetimibe | Ezetimibe | 58 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | 11 |
| Meclizine Hcl | Meclizine Hcl | 51 | 17 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 22 |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 19 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Azithromycin | Azithromycin | 38 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 12 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 12 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Methimazole | Methimazole | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.38 · 11 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, MOUNJARO, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UZEDY, VRAYLAR, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error